Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

HAYWARD, Calif., May 13, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31st, 2013.

First Quarter 2013 Financial Results:

Loss from operations, which included a non-recurring and non-cash charge of approximately $1.5 million in stock-based compensation, was $6.9 million for the first quarter of 2013, compared to $20.1 million for the first quarter of 2012.  The decrease in loss from operations primarily resulted from a decrease in research and development expenses to $4.9 million from $17.7 million and a decrease in general and administrative expenses from $2.3 million to $2.0 million.  The decrease in research and development expenses in the first quarter of 2013 compared to the first quarter of 2012 was primarily the result of decreased direct and indirect clinical study costs as the Company focuses on the development of blisibimod for systemic lupus erythematosus, or lupus, and IgA nephropathy, an orphan disease.  The Company also experienced lower manufacturing spending as manufacturing of blisibimod for patient dosing in the on-going clinical studies was completed in 2012.  The decrease in general and administrative expenses for the first quarter of 2013 compared to the first quarter of 2012 was primarily due to reduced spending on consulting and professional services and reflects the Company's ongoing cost reduction efforts.

Net loss for the quarter ended March 31, 2013 was $7.6 million, or $0.06 loss per basic and diluted share, compared with loss of $20.9 million, or $0.51 loss per basic and diluted share for the quarter ended March 31, 2012. The decrease in net loss per basic and diluted share in the first quarter of 2013 as compared to the first quarter of 2012 was primarily the result
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Calif. , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. ... , PhD, Chief Executive Officer, will present a corporate overview ... 2015, in New York City . ... presentation at 11:30 am ET at the Millennium Broadway Hotel. ... at 3:00 pm ET at the St. Regis Hotel. ...
(Date:8/26/2015)... August 27, 2015 ... the genotyping technology, its application and products ... nucleotide polymorphism (SNP) genotyping industry analysis are ... report on genotyping market by technology, application ... profiling 10 major companies and supported with ...
(Date:8/26/2015)... , Aug. 26, 2015 The North American ... a CAGR of 7.8% during the forecast period, 2014 ... cataract surgery devices market in 2014 and accounted for ... cataract surgery devices market is expected to witness growth ... increasing strategic expansion of the companies and continuous rise ...
Breaking Medicine Technology:SciClone To Present At Two Investor Conferences On September 10, 2015 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 18, 2011 Certain brain processes happen in the ... which has made pinpointing these events virtually impossible. The ... to capture brain electrical activity measured in milliseconds, and ... brain disorders and diseases. Swinburne University of Technology is ...
... CINCINNATI, April 18, 2011 HealthWarehouse.com, Inc. (OTC: HEWA) ... its financial results for the year ended December 31, ... 31, 2010, the Company,s net sales increased $1,908,223 to ... 2009. This was driven by growth in the Company,s ...
Cached Medicine Technology:Australian Center Readies Brain Research Program for Addition of Elekta MEG System 2Australian Center Readies Brain Research Program for Addition of Elekta MEG System 3Australian Center Readies Brain Research Program for Addition of Elekta MEG System 4HealthWarehouse.com Reports 278% Year-Over-Year Prescription Growth 2HealthWarehouse.com Reports 278% Year-Over-Year Prescription Growth 3
(Date:8/27/2015)... PLAINSBORO, N.J. and WILMINGTON, Del. (PRWEB) , ... August 27, 2015 ... ... at Texas Children’s Hospital, will be the guest speaker at CURE® magazine’s 3rd ... meeting of hematologists. , Dr. Arnold will be among hundreds of attendees honoring eight ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the premium ... Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko competes in ... and recovery. , With a focus on technology and comfort, Zensah® has developed ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... high-performance blending all in one machine with the Nutri Ninja® Auto-iQ Pro Complete ... next-generation Auto-iQ™ Smooth Boost™ Technology that takes drink customization to a whole new ...
(Date:8/27/2015)... ... 2015 , ... Sunbelt® Bakery, maker of delicious granola snacks that have a ... of how protein bars should taste with the launch of its new line of ... the market today. , The new Protein Delights are individually wrapped wafer bars ...
(Date:8/27/2015)... ... August 27, 2015 , ... "I need a little help supporting and stabilizing ... from Camp Hill, Pa. "I developed this support handle to give me the extra ... SHOWER GRIP to provide a helping hand when stepping into or out of the ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
... MYL ) today announced its plans to purchase ... shareholders pursuant to a voluntary delisting offer. Mylan, through ... and controls more than 76% of its voting rights. ... accretive to Mylan,s 2009 earnings. Mylan Vice Chairman and ...
... and SEATTLE, March 26 BioMosaics Inc., ... that its monoclonal antibody product (clone 1G12) ... validated for use as an immunohistochemical test ... PhenoPath Laboratories. PhenoPath Laboratories is a state-of-the-art ...
... Edward M. Kennedy and Kay Bailey Hutchison introduced ... by modernizing and advancing the national cancer program ... Cancer ALERT (Access to Life-saving Early detection, Research ... re-assess the national cancer program and improve cancer ...
... March 26 Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) ... that Roche has completed its acquisition of Genentech pursuant ... wholly-owned member of the Roche Group. Roche had announced ... tender offer, which expired on Wednesday, March 25. In ...
... 26 California has one of the top ... more people become,uninsured due to the rapidly increasing ... that helps people without prescription coverage,save on many ... to access necessary medications. During "Cover the Uninsured ...
... Authentidate Holding Corp. (Nasdaq: ... Exchange and workflow management services, today announced that the ... New York dismissed with prejudice shareholder class actions filed ... certain current and former directors and former officers. The ...
Cached Medicine News:Health News:Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges 2Health News:Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:The AACR commends Senators Kennedy and Hutchison on the 21st Century Cancer ALERT Act 2Health News:Roche Completes Acquisition of Genentech 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 3Health News:Authentidate Holding Corp. Successfully Defends Against Class Action Lawsuits 2Health News:Authentidate Holding Corp. Successfully Defends Against Class Action Lawsuits 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: